Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1672416

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes and Obesity: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of the powers of the Medicines and Healthcare products Regulatory Agency to prevent the illegal online (a) marketing and (b) sale of (i) second generation GLP-1 weight management and (ii) other potentially hazardous medications.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	3295
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) has the same powers available to other regulatory organisations and law enforcement agencies when addressing offending online. MHRA takes proportionate action, on a case-by-case basis, to enforce the Human Medicines Regulations 2012 in respect of the illegal sale and supply of second generation glucagon-like peptide 1 weight management medications and other potentially hazardous medications. In cases of serious non-compliance, the agency has the power to undertake formal criminal investigations and, where appropriate and evidentially supported, prosecution through the Crown Prosecution Service.</p><p>As this is primarily an online threat, MHRA works closely with social media providers, search engines and the broader internet industry to prevent and disrupt illegal sales and to identify and bring those responsible into compliance with the regulations.</p><p>Through its #Fakemeds campaign, MHRA uses social media and other channels to share safety advice and guidance with the public. The aim is to help patients protect their health by offering quick and easy tools and resources to help them avoid fake medical products when shopping online. With practical tips on how to recognise illegally trading websites and case studies of commonly falsified medicines, it also aims to educate the public on the dangers of buying unlicensed or fake medicines and empower them to make the right choices for their health.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/11/2023 12:27:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1672417

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes and Obesity: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many prosecutions have been brought against sellers of (a) second generation GLP-1 weight management medications and (b) other potentially hazardous medications on the internet over the last 12 months.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	3296
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>To date, no prosecutions have been brought against those involved in the illegal sale of glucagon-like peptide 1 medicines although the Medicines and Healthcare products Regulatory Agency (MHRA) and Humberside Police were involved in executive action as recently as 23 November 2023 following an MHRA investigation into the alleged illegal supply of these products. During the last 12 months, MHRA has completed nine investigations involving the online sale of hazardous medicines. These investigations are at different stages within the criminal justice system.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/11/2023 12:26:11 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1670755

registered interest
date	17/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alzheimer's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has had recent discussions with NHS Scotland on ensuring that newly-licensed Alzheimer's treatments are made available to patients as soon as possible in all regions of the UK.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	2411
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>The Department has liaised with colleagues in the Scottish Government to discuss preparations for the introduction and potential adoption of new medicines for Alzheimer’s disease, should they receive regulatory approval.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/11/2023 16:21:24 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1670761

registered interest
date	17/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to incentivise overseas researchers to undertake clinical trials on dementia research in the UK.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	2412
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>The Department, via the National Institute for Health and Care Research (NIHR), invests in world-class facilities, expertise and a skilled delivery workforce for clinical research in the National Health Service and wider health and care system. This infrastructure has been operational for many years as a centralised system, creating a unique offer in the United Kingdom for overseas researchers to undertake clinical trials, including in dementia. This includes the Dementia Translational Research Collaboration, which plays a critical role in coordinating UK dementia research in early phase clinical trials and the NIHR Clinical Research Network Dementias and Neurodegeneration Specialty, which supports patients, the public and health and care organisations across England to participate in dementia research spanning the full translational research pathway.</p><p>The multi-year Vision for the Future of UK Clinical Research Delivery was published on 23 March 2021 and sets out our ambition to create a patient-centred, pro-innovation and digitally enabled clinical research environment. The Government also commissioned Lord O’Shaughnessy to conduct a review into commercial clinical trials following a drop in the UK’s performance during and following the pandemic. The Government published the full response to the Lord O’Shaughnessy review on 22 November 2023. The response provides an update on the significant progress we have made in recovering clinical trial performance and set out our plan, backed by up to £121 million, to strengthen the clinical trials ecosystem and make it quicker and easier for NHS patients to access the latest innovative treatments through clinical research.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/11/2023 15:55:49 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1354977

registered interest
date	13/09/2021
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Electric Vehicles
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what steps his Department is taking to inform the public of the benefits of electric powered vehicles.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	48303
answer	answer is ministerial correction date of answer 21/09/2021 answer text <p>On 9 September 2021 the Government published an informational leaflet addressing commonly held misconceptions and concerns regarding electric vehicles (EVs). This comes in addition to the Go Ultra Low initiative, which since launching in 2014 has seen Government collaborate with industry and other stakeholders to provide basic, practical advice for those considering making the switch to zero emission driving. The Government will continue to build on this work as EVs sales increase and become more commonplace on our roads.</p><p> </p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/09/2021 12:56:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day